Straits Times Index
3,296.31 -8.68 (-0.26%) Nikkei
38,782.08 -138.18 (-0.36%) Hang Seng
19,401.43 +24.90 (+0.13%) FTSE 100
8,438.65 -7.15 (-0.08%) Bitcoin USD
65,447.47 -554.13 (-0.84%) CMC Crypto 200
1,376.44 -17.61 (-1.26%)
Genelux Corporation (GNLX)
After hours:
| Previous close | 3.6400 |
| Open | 3.6200 |
| Bid | 3.5700 x 500 |
| Ask | 3.6400 x 400 |
| Day's range | 3.5000 - 3.6600 |
| 52-week range | 3.0600 - 40.9800 |
| Volume | |
| Avg. volume | 128,887 |
| Market cap | 98.268M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.00 |
GlobeNewswireGenelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. “Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Looking ahead, we are excited about advancing Olvi-Vec into a
Simply Wall St.Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders
Key Insights Significant control over Genelux by individual investors implies that the general public has more power to...
ZacksDown -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
